Hereditary cancer genetic testing has evolved significantly over the last decade. What once focused primarily on BRCA1 and BRCA2 mutations now includes panels analyzing 26 or more inherited gene mutations linked to elevated risk across multiple cancers, including breast, ovarian, colorectal, pancreatic, and prostate cancer, all from a single sample.
The purpose of genetic testing remains the same: identifying inherited mutations that may increase a person’s lifetime cancer risk. What has changed is how much testing can now reveal who qualifies for it, and how early that information can guide prevention, screening, and treatment decisions. Clinical guidelines have expanded rapidly, and many individuals who would not have qualified for testing a few years ago may now benefit from it.
A positive result does not mean someone will develop cancer. It means there is an increased inherited risk, allowing doctors and patients to take a more proactive approach through earlier screenings, prevention strategies, and personalized medical planning. A negative result can also provide valuable clarity and reassurance, helping individuals better understand their risk profile and recommended monitoring options.
The articles in this section explore the most important questions surrounding hereditary cancer genetic testing, including which cancers are inherited, which gene mutations matter most, who should consider testing, how testing works, what results actually mean, and what steps may follow after an elevated-risk finding.
Understanding inherited cancer risk is actionable information. The earlier it is identified, the more opportunities there may be to make informed decisions about long-term health.
Explore the articles below to learn more about hereditary cancer testing and where to start.
_Webflow%20(1).png)
%20(1).png)
.png)
